Free Newsletter
U.K. demands all SSRI data
Put your cards on the table, ladies and gentlemen. A U.K. minister is calling on drug companies to hand over all their data on antidepressants to the National Institute for Health and Clinical Excellence. NICE, you'll recall, is reviewing its guidelines for the use of SSRI drugs, aiming to issue new treatment advice this fall. Failing to hand over that data "would leave the inevitable impression they had something to hide," the minister said. In the past, another official said, the government has been unable to get access to unpublished trials.
The request comes on the heels of last week's study showing that SSRIs were effective only in the most severely depressed patients. Despite the U.K.'s official position that drugs shouldn't be the first line of defense against depression, they're among Britain's most prescribed meds with more than 31 million scrips in 2006.
- read the report from the Guardian
Related Articles:
Study: Antidepressants useless for most. Report
Antidepressants--Top 10 Warnings and Recalls of 2007. Report
Positive data more likely to find its way to public. Report
U.K. ratchets up antidepressant warnings. Report
Suicide stats fuel debate over SSRI drugs. Report
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: